Kourosh Hayatigolkhatmi

Project: Investigating the role of epigenome in the establishment of Acute Myeloid Leukaemia

European Institute of Oncology (IEO)



About Kourosh

Kourosh was graduated from Mashhad University of Medical Sciences, where, he embarked on his career as a medical laboratory scientist, interested in human genetics. He did his final BSc research on prevalence of ß-thalassemia in North-Eastern Iran (DOI:HTTPS://doi.org/10.4084/mjhid.2018.042).

After a year of clinical practice, his passion for human genetics brought him to Glasgow, UK, where, he studied his MSc in medical genetics and genomics in the University of Glasgow. During his MSc, he chose to specialise in cancer studies after being enrolled in the “frontiers in cancer sciences” optional course. Hence, he chose to do his MSc dissertation on investigation of a minor groove-binding polyamide (PA) to inhibit E2F1 in chronic myeloid leukaemia (CML), under supervision of Dr. Heather Jørgensen, in the Paul O’Gorman leukemia research centre of Glasgow. They have investigated their synthetic programmed PA’s ability to inhibit E2F1 transcriptional activity so causing cell death to CML primitive leukaemic stem cells. Blast crisis (BC) KCL22 cells and primary chronic phase (CP) CML CD34+cells were assessed after treatment with PA, tyrosine kinase inhibitor and their combination (CP cells’ results: DOI: HTTPS://doi.org/10.1016/j.bcmd.2017.11.002and BC cells’ results: DOI: HTTPS://doi.org/10.1016/j.bmcl.2019.07.049).

Currently, Kourosh is a PhD researcher in Prof. Saverio Minucci’s laboratory, department of experimental oncology of IEO in Milan, Italy. At this point, he is eagerly trying obtaining a deeper understanding of underlying epigenetic regulatory machinery involved in acute myeloid leukaemia initiation and maintenance. He is looking at epigenomic and also genomic alterations. Hence, he is utilising various molecular and cellular biology techniques e.g. ChIP-Seq, ATAC-Seq, RNA-Seq, qPCR, CRISPR/Cas9, etc. both in vitroand invivo.